An independent intelligence board aggregating credible research, preprints, clinical findings, biohacking experiments, and community discussions on therapeutic peptides, longevity science, and evidence-based anti-aging. Stories are scored for relevance, credibility, novelty, momentum, and practicality so the most important findings surface first.
The American College of Physicians (ACP) has updated its guidance and now recommends two drugs—semaglutide and tirzepatide—as first-line medication options to treat obesity. In plain terms, a major medical group is saying these medicines should be considered early in care for people with obesity, alongside diet, exercise, and other therapies. This is a guidance statement, not a law, but it signals growing acceptance of these drugs for weight management. Semaglutide and tirzepatide are medicines that mimic hormones your gut normally makes after you eat. Semaglutide acts like a hormone that tells your brain you’re full and slows how fast your stomach empties. Tirzepatide acts like two gut hormones at once, so it can reduce appetite and affect how your body handles sugar. These are injectable medications given under the skin and they’re not the same as older weight-loss pills; they work by changing hunger and digestion signals. The ACP’s recommendation is based on clinical trials that showed these drugs help many people lose more weight than placebo (a dummy treatment) when combined with lifestyle changes. Most of the evidence comes from randomized trials in adults, not from small anecdotes or animal studies. The amount of weight loss varied by drug and study, but semaglutide and tirzepatide generally produced substantially more weight loss than diet and exercise alone in trial settings. The guidance reflects that benefit but also notes that effects are measured in controlled studies and may differ in everyday practice. This matters because obesity is common and contributes to many health problems like diabetes and heart disease. If more doctors follow this advice, more patients might be offered these medications earlier, which could improve health outcomes for people who haven’t had success with lifestyle changes alone. People with obesity who are struggling to lose weight despite diet and activity may want to know that effective prescription options exist and are being endorsed by a major medical society. There are important caveats. These drugs can cause side effects like nausea, diarrhea, and vomiting, and they’re not appropriate for everyone. Long-term safety beyond the trial periods is still being studied. Cost and insurance coverage vary; these medicines can be expensive and may not be covered for weight loss by all plans. They also require ongoing use for sustained weight control—stopping them often leads to weight regain. Pregnant people should not use them, and there are specific medical conditions and histories that make them unsuitable for some patients. Bottom line: A major medical group now recommends semaglutide and tirzepatide as primary drug options for treating obesity, reflecting good trial results but also raising practical questions about side effects, cost, and long-term use.
Source: AJMC